Recent advancements in biomarker research in schizophrenia: mapping the road from bench to bedside
- PMID: 35239143
- DOI: 10.1007/s11011-022-00926-5
Recent advancements in biomarker research in schizophrenia: mapping the road from bench to bedside
Abstract
Schizophrenia (SZ) is a severe progressive neurodegenerative as well as disruptive behavior disorder affecting innumerable people throughout the world. The discovery of potential biomarkers in the clinical scenario would lead to the development of effective methods of diagnosis and would provide an understanding of the prognosis of the disease. Moreover, breakthrough inventions for the treatment and prevention of this mysterious disease could evolve as a result of a thorough understanding of the clinical biomarkers. In this review, we have discussed about specific biomarkers of SZ an emphasis has been laid to delineate (1) diagnostic biomarkers like neuroimmune biomarkers, metabolic biomarkers, oligodendrocyte biomarkers and biomarkers of negative and cognitive symptoms, (2) therapeutic biomarkers like various neurotransmitter systems and (3) prognostic biomarkers. All the biomarkers were evaluated in drug-naïve (at least for 4 weeks) patients in order to achieve a clear comparison between schizophrenic patients and healthy controls. Also, an attempt has been made to elucidate the potential genes which serve as predictors and tools for the determination of biomarkers and would ultimately help in the prevention and treatment of this deadly illness.
Keywords: Biomarkers; Cognition; Negative symptoms; Neurodegeneration; Neuroinflammation; Schizophrenia.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Similar articles
-
Theranostic Biomarkers for Schizophrenia.Int J Mol Sci. 2017 Mar 30;18(4):733. doi: 10.3390/ijms18040733. Int J Mol Sci. 2017. PMID: 28358316 Free PMC article. Review.
-
A preliminary analysis of LncRNA biomarkers for schizophrenia.Epigenomics. 2021 Sep;13(18):1443-1458. doi: 10.2217/epi-2021-0223. Epub 2021 Sep 16. Epigenomics. 2021. PMID: 34528440
-
hsa_circRNA_104597: a novel potential diagnostic and therapeutic biomarker for schizophrenia.Biomark Med. 2019 Apr;13(5):331-340. doi: 10.2217/bmm-2018-0447. Epub 2019 Feb 20. Biomark Med. 2019. PMID: 30781971
-
Abnormal C-reactive protein blood levels as a specific biomarker of major depression and non-remission under antidepressants in schizophrenia.Prog Neuropsychopharmacol Biol Psychiatry. 2020 Mar 8;97:109800. doi: 10.1016/j.pnpbp.2019.109800. Epub 2019 Oct 30. Prog Neuropsychopharmacol Biol Psychiatry. 2020. PMID: 31676465
-
Schizophrenia and bipolar disorder: The road from similarities and clinical heterogeneity to neurobiological types.Clin Chim Acta. 2015 Sep 20;449:49-59. doi: 10.1016/j.cca.2015.02.029. Epub 2015 Feb 20. Clin Chim Acta. 2015. PMID: 25704299 Review.
Cited by
-
The Interrelation between Interleukin-2 and Schizophrenia.Brain Sci. 2022 Aug 30;12(9):1154. doi: 10.3390/brainsci12091154. Brain Sci. 2022. PMID: 36138890 Free PMC article. Review.
-
Potential diagnostic biomarkers for schizophrenia.Med Rev (2021). 2022 Aug 2;2(4):385-416. doi: 10.1515/mr-2022-0009. eCollection 2022 Aug. Med Rev (2021). 2022. PMID: 37724326 Free PMC article. Review.
-
Plasma metabolomics reveals the intervention mechanism of different types of exercise on chronic unpredictable mild stress-induced depression rat model.Metab Brain Dis. 2024 Jan;39(1):1-13. doi: 10.1007/s11011-023-01310-7. Epub 2023 Nov 24. Metab Brain Dis. 2024. PMID: 37999885
References
-
- Acar E, Schenker C, Levin-Schwartz Y et al (2019) Unraveling diagnostic biomarkers of schizophrenia through structure-revealing fusion of multi-modal neuroimaging data. Front Neurosci 13. https://doi.org/10.3389/fnins.2019.00416
-
- Al-Hakeim HK, Almulla AF, Maes M (2020) The Neuroimmune and Neurotoxic Fingerprint of Major Neurocognitive Psychosis or Deficit Schizophrenia: a Supervised Machine Learning Study. Neurotox Res 37:753–771. https://doi.org/10.1007/s12640-019-00112-z - DOI - PubMed
-
- Al-Hakeim HK, Mousa RF, Al-Dujaili AH, Maes M (2021) In schizophrenia, non-remitters and partial remitters to treatment with antipsychotics are qualitatively distinct classes with respect to neurocognitive deficits and neuro-immune biomarkers: results of soft independent modeling of class analogy. Metab Brain Dis 36:939–955. https://doi.org/10.1007/s11011-021-00685-9 - DOI - PubMed
-
- Ayari F, Ben Chaaben A, Ben Ammar H et al (2020) Association of high-sensitivity C-reactive protein with susceptibility to Schizophrenia in Tunisian population. Encephale 46:241–247. https://doi.org/10.1016/j.encep.2019.10.001 - DOI - PubMed
-
- Brodbeck C, Presacco A, Simon JZ (2018) Neural source dynamics of brain responses to continuous stimuli: Speech processing from acoustics to comprehension. NeuroImage 172:162–174. https://doi.org/10.1016/j.neuroimage.2018.01.042 - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical